ESMO 2026 Features Six Mirvetuximab Soravtansine Studies Across Ovarian Cancer Settings
Start here
The 2026 ESMO congress includes six abstracts on mirvetuximab soravtansine (MIRV), an antibody-drug conjugate targeting folate receptor alpha. The studies span first-line and responder analyses in FRα-positive platinum-resistant ovarian cancer, long-term follow-up from Chinese real-world data, pretreatment albumin as a potential predictive marker, the FLORENZA combination regimen, and hematologic safety of a carboplatin combination in platinum-sensitive ovarian cancer. Together the abstracts broaden the evidence base for MIRV beyond its established indications, probing earlier lines of therapy, combination strategies and patient selection. Full congress presentations and peer-reviewed results are still pending, and the maturity of the real-world and biomarker findings will determine how quickly they inform clinical practice.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comESMO 2026 Presents Six Mirvetuximab Soravtansine Studies Spanning Platinum-Resistant First-Line, Platinum-Sensitive Combinations and Chinese Real-World Data
The 2026 ESMO congress includes six mirvetuximab soravtansine (MIRV) abstracts, covering a post hoc analysis of first-line therapy and responders in FRα-positive platinum-resistant ovarian cancer, long-term follow-up from Chinese real-world data, pretreatment albumin as a predictor, the FLORENZA combination regimen, and hematologic safety of carboplatin combination in platinum-sensitive ovarian cancer.
Heat trend for this story
Heat now 9·Peak in the comparable set 10 (Oct 24 20:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.